Floatz logo

TOREMIFENE

Breast Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

208 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB

View all 50 →

Same molecule, other indications

TOREMIFENE is also rated in:

prostate intraepithelial neoplasiaDormant
BB
Indicative · Phase 3
68 / 100
View asset →
breast carcinoma in situDormant
BB
Indicative · Phase 4
65 / 100
View asset →
invasive breast carcinomaDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →